The first large-scale natural history study of sepsis reveal, that even when the disease looks the same clinically, not all patents with sepsis have the same immune response. This study point out to the fact that the past interpretation of how the immune system responds to infection - interpretations on which many experimental treatments were based -to be incorrect.
Sepsis developes as a result of the body's inflammatory response to an infection and can often lead to organ failure and death. Sepsis is the 10th most leading cause of death in America and this nearly 1 million people have developed the problem. Though there has been an increase in the number of cases each year the condition of the disease is still unknown. This study by the University of Pittsburgh School of Medicine was published in the in the August 13/27 issue of the Archives of Internal Medicine.
Researchers at the University of Pittsburgh believe that these treatments failed, at least in part, because of insufficient data to fully understand the complexity and variability of the inflammatory response to sepsis.
"With sepsis, we're dealing with one of the deadliest diseases, yet we know so little about the condition. The situation is similar to what this country experienced over 50 years ago with heart disease and stroke - we knew that too many people were dying of cardiovascular disease, but we didn't know enough about the disease to effectively treat and prevent it," said Derek C. Angus, M.D., M.P.H., professor and vice chair of research, department of critical care medicine, University of Pittsburgh School of Medicine.
"In response, the National Institutes of Health embarked on the Framingham Heart Study, the results of which have influenced everything we know about the prevention and treatment of cardiovascular disease. With our study, we're hoping to do the same for sepsis, providing a greater understanding of the disease on which future treatment and prevention strategies can be based."
For this analysis, researchers evaluated data from 1,886 of the study participants who were hospitalized with community-acquired pneumonia (CAP), the leading cause of severe sepsis. More than 30 percent of the subjects developed severe sepsis, of whom 26 percent died.
To determine the inflammatory response in the participants with CAP, the researchers measured cytokine levels daily for the first week of hospitalization and then weekly thereafter. They found that 82 percent of the participants with CAP had elevated cytokine levels.
Levels were highest when the subject presented at the emergency room, tapered down over the first few days, but remained elevated throughout the first week of hospitalization - even after the clinical signs of infection had subsided. Levels were highest in those with fatal severe sepsis, lowest in those with CAP but no sepsis.
"Our data show that much of what we previously thought about the role the inflammatory response plays in sepsis was wrong or incomplete. We had thought the inflammatory response to infection was relatively short-lived, just a few days, and that it was similar in patients with similar clinical signs. Instead, we found that the inflammatory response was extremely variable across patients—more than 50-fold differences were seen in some markers.
Additionally, we found that the inflammatory response extends past the outward symptoms, far longer than previous data would suggest, and far longer than the courses of therapies used in unsuccessful clinical trials of experimental agents," said John A. Kellum, M.D., professor, department of critical care medicine, University of Pittsburgh School of Medicine. "We also found that the difference between the inflammatory response in a patient with a good outcome and a patient with a bad outcome is only a matter of degree."
The Pitt researchers say that in light of their results, treatments that completely abolish a specific component of the inflammatory response would be ineffective, and could be dangerous, since the inflammatory response is needed to address the underlying infection.
Instead, they believe that therapies that address the chronic inflammatory response after sepsis and those that act more broadly on multiple components may yield better results.
"No one really knows why some people develop sepsis following an infection," said Scott Somers, Ph.D., who oversees sepsis grants at the National Institute of General Medical Sciences, which partially funded the work. "This large study gives us a much clearer picture of sepsis—and shows us that it's even more complicated than we thought."
The researchers plan to release several other reports from the GenIMS study in the coming months, which they hope will provide more clues to the condition.